摘要
目的 探究对中晚期胃癌患者采取化疗联合参苡健中汤治疗的近期疗效,并观察其对患者免疫指标及生存质量的影响。方法 选取65例中晚期胃癌患者,以奇偶数字法分为对照组(32例)和观察组(33例)。对照组采取化疗进行治疗,观察组在对照组基础上联合参苡健中汤进行治疗。比较两组患者免疫指标、肿瘤标志物、胃肠功能、生存质量评分、近期疗效。结果 治疗后,两组患者免疫球蛋白A、免疫球蛋白G、免疫球蛋白M比本组治疗前更高,且观察组免疫球蛋白A(1.76±0.37)g/L、免疫球蛋白G(13.39±1.85)g/L、免疫球蛋白M(2.06±0.55)g/L比对照组的(1.40±0.31)、(11.61±2.03)、(1.70±0.62)g/L更高(P<0.05)。治疗后,两组患者糖类抗原125(CA125)、糖类抗原199(CA199)、癌胚抗原(CEA)比本组治疗前更低,且观察组CA125(11.27±0.98)U/ml、CA199(16.93±1.06)U/ml、CEA(1.70±0.35)ng/ml比对照组的(21.82±1.03)U/ml、(20.69±1.45)U/ml、(4.32±0.26)ng/ml更低(P<0.05)。治疗后,两组患者胃蛋白酶原Ⅰ(PGⅠ)比本组治疗前更高、胃泌素(GAS)比本组治疗前更低,且观察组PGⅠ(90.51±12.91)μg/L比对照组的(83.42±13.39)μg/L更高、GAS(15.60±2.56)ng/L比对照组的(17.75±2.92)ng/L更低(P<0.05)。治疗后,两组患者生存质量评分比同组治疗前更低,且观察组的(41.38±3.52)分比对照组的(56.41±3.73)分更低(P<0.05)。观察组总缓解率87.88%比对照组的62.50%更高(P<0.05)。结论 化疗联合参苡健中汤能够提高中晚期胃癌患者生存质量,且具有改善患者免疫指标、调节患者胃肠功能指标及肿瘤标志物的异常等作用。
Objective To expolre the short-term efficacy of chemotherapy combined with Shenyi Jianzhong Decoction in the treatment of advanced gastric cancer patients,and observe its influence on the immune indexes and quality of life of patients.Methods 65 patients with advanced gastric cancer were divided into a control group(32 cases)and an observation group(33 cases)by odd-even number method.The control group was treated with chemotherapy,and the observation group was treated with Shenyi Jianzhong Decoction on the basis of the control group.The immune indexes,tumor markers,gastrointestinal function,quality of life score and short-term efficacy were compared between the two groups.Results After treatment,the immunoglobulin A,immunoglobulin G and immunoglobulin M in both groups were higher than those before treatment;the observation group had immunoglobulin A of(1.76±0.37)g/L,immunoglobulin G of(13.39±1.85)g/L and immunoglobulin M of(2.06±0.55)g/L,which were higher than(1.40±0.31),(1.40±0.31)and(1.70±0.62)g/L of the control group(P<0.05).After treatment,the carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)in both groups were lower than those before treatment;the observation group had CA125 of(11.27±0.98)U/ml,CA199 of(16.93±1.06)U/ml and CEA of(1.70±0.35)ng/ml,which were lower than(21.82±1.03)U/ml,(20.69±1.45)U/ml and(4.32±0.26)ng/ml in the control group(P<0.05).After treatment,the levels of pepsinogenⅠ(PG-Ⅰ)and gastrin(GAS)in both groups were higher than those before treatment;the observation group had higher PG-Ⅰof(90.51±12.91)μg/L than(83.42±13.39)μg/L in the control group,and lower GAS of(15.60±2.56)ng/L than(17.75±2.92)ng/L in the control group(P<0.05).After treatment,the quality of life score of the two groups was lower than that before treatment,and the observation group[(41.38±3.52)points]was lower than the control group[(56.41±3.73)points](P<0.05).The total remission rate of 87.88%in the observation group was higher than 62.50%in the control group(P<0.05).Conclusion Chemotherapy combined with Shenyi Jianzhong Decoction can improve the quality of life of patients with advanced gastric cancer,and has the role of improving immune indexes,regulating gastrointestinal function indicators and abnormal tumor markers.
作者
张永凤
ZHANG Yong-feng(Jiyang District Hospital of Traditional Chinese Medicine,Jinan 251400,China)
出处
《中国现代药物应用》
2024年第18期133-136,共4页
Chinese Journal of Modern Drug Application
关键词
化疗
参苡健中汤
中晚期胃癌
免疫指标
生存质量
Chemotherapy
Shenyi Jianzhong Decoction
Advanced gastric cancer
Immune indexes
Quality of life
